Loading publications…
The last 5 uploaded publications
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast, Wesley Huisman, Rob van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Olivia A. C. Lamers, Jan Pieter R. Koopman, Annelieke C. Kruithof, Ingrid M. C. Kamerling, Romy C. Dijkland, Alicia C. de Kroon, Shohreh Azimi, Mariet C.W. Feltkamp, Marjan Kuijer, Simon P. Jochems, Mirjam H.M. Heemskerk, Frits R. Rosendaal, Meta Roestenberg, Leo G. Visser, Anna H.E. Roukens (2024). Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial. npj Vaccines, 9(1), DOI: 10.1038/s41541-023-00785-w.
Article126 days agoSafety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study
Geert V.T. Roozen, Margaretha Prins, Rob van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Annelieke C. Kruithof, Mariet C.W. Feltkamp, Marjan Kuijer, Frits R. Rosendaal, Meta Roestenberg, Leo G. Visser, Anna H.E. Roukens (2022). Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study. Annals of Internal Medicine, 175(12), pp. 1771-1774, DOI: 10.7326/m22-2089.
Article126 days agoIntradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
Geert V.T. Roozen, Manon L. M. Prins, Corine Prins, Jacqueline J. Janse, Heidi L.M. De Gruyter, Cilia R. Pothast, Wesley Huisman, Jan Pieter R. Koopman, Olivia A.C. Lamers, Marjan Kuijer, Sebenzile K. Myeni, Rob van Binnendijk, Gerco den Hartog, Mirjam H.M. Heemskerk, Simon P. Jochems, Mariet C.W. Feltkamp, Marjolein Kikkert, Frits R. Rosendaal, Meta Roestenberg, Leo G. Visser, Anna H.E. Roukens (2024). Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose. Clinical Microbiology and Infection, DOI: 10.1016/j.cmi.2024.03.028.
Article126 days agoTolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy
Geert V.T. Roozen, Margaretha Prins, Rob van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Annelieke C. Kruithof, Mariet C.W. Feltkamp, Marjan Kuijer, Frits R. Rosendaal, Meta Roestenberg, Leo G. Visser, Anna H.E. Roukens (2021). Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv (Cold Spring Harbor Laboratory), DOI: 10.1101/2021.07.27.21261116.
Preprint126 days ago